Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRTEN SPK: Conversion to Envarsus XR in SPK Recipients
NCT03769298Phase 3Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2019
- Primary completion
- Dec 2027
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tacrolimus + Wuzhi capsule in essential tremor (ET) and transplant rejection, sponsored by University of Wisconsin–Madison. Primary endpoints: Fahn-Tolosa-Marin Tremor Rating Scale at 6 months, Quality of Life in Essential Tremor Questionnaire at 6 months and 1 more. Started Feb 2019; status: recruiting.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
essential tremor (ET)transplant rejection
Beyond the preview
Go deeper on NCT03769298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769298.